Ipsen has turned to another Paris-based biopharma company for its next CEO.

Sanofi Pasteur chief David Loew — who’s been leading one of the most advanced efforts to develop vaccines for Covid-19 — is making the journey to Ipsen, 5 months after David Meek jumped ship to run a startup in late-stage development.

Loew arrives as Ipsen works to get back on track with their rare bone disease drug palovarotene, picked up in the $1.3 billion Clementia buyout, which was slammed with a partial hold after researchers observed cases of “early growth plate closure” in patients under the age of 14. But they are pushing ahead with the over-14 crowd after writing down slightly more than half of its initial development.

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.

The ex-CEO of Harmony Biosciences — as well as former board member for Biohaven — has agreed to plead guilty to two counts of mail fraud after getting caught up in the college admissions scandal.

Charged with paying Georgetown University’s former tennis coach more than $50,000 to get his daughter admitted to the university as a new recruit for the team, Bob Repella took the plea deal, which comes with a recommended sentence of 10 months in prison, with a year of supervised release and a $40,000 fine.

At the turn of the millennium, finishing up her PhD in theoretical physics, Iya Khalil found the career paths in front of her wanting. Academic postings were tough to get, but she couldn’t envision applying all she’s learned to predict stocks on Wall Streets, as some of her contemporaries did.

She was working on models of two-dimensional electron gas, a topic in solid-state physics, when she met Colin Hill, the fellow Cornell physicist with whom she would later start a company named Gene Network Sciences.

Moncef Slaoui stepped off Moderna’s board of directors on Friday and pivoted straight into the high profile role heading the Trump administration’s Project Warp Speed, where he’ll be in charge of accelerating Moderna’s — and others — vaccines to a rapid release for a pandemic weary world.

The news became official mid-day Friday after numerous reports earlier that he had been picked off the short list of candidates.

In wide-ranging congressional testimony, the ousted head of an agency at the center of the federal government’s Covid-19 vaccine and treatment response criticized the Trump administration for a slow-footed federal response that could resound throughout the course of the pandemic.

“I believe we could have done better,” Rick Bright, former chief of the Biomedical Advanced Research and Development Authority (BARDA), told a House subcommittee. “We don’t have the right leadership for this response and we don’t have the right plan for this response.”